ViiV has 'another formidable asset' in rivalry with Gilead

Claims by ViiV Healthcare’s chief executive Deborah Waterhouse (pictured above) that her company is  doing more than just playing second fiddle to US biotech Gilead Science (Nasdaq: GILD) in the HIV space have been backed up by an analyst at GlobalData.

Positive top-line results from ViiV’s Phase III GEMINI 1 and GEMINI 2 studies are a major breakthrough in its strategy to gain an advantage in the highly competitive HIV market through the development of two-drug single-tablet regimens (STRs), according to James Mather, pharma analyst at the data and analytics company.

These two-drug STRs aim to lessen the toxicity and side effect burden of current treatments that combine three or four medicines